Literature DB >> 23547017

AhR expression is increased in hepatocellular carcinoma.

Ziyu Liu1, Xing'an Wu, Fanglin Zhang, Lurong Han, Guoqiang Bao, Xianli He, Zhikai Xu.   

Abstract

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor implicated in multiple cellular processes and its expression has been shown to play a critical role in tumorigenesis. However, the role of AhR in tumorigenesis of hepatocellular carcinoma remains unclear. In the current study, we investigated the role of AhR in hepatocellular carcinoma tumorigenesis and progression by (a) measuring the expression levels of AhR in liver lesions and (b) assessing the correlation between AhR expression and clinicopathologic parameters. The tissue microarray used in this study contained hepatocellular carcinoma tissues (n = 94), cancer adjacent normal hepatic tissues (n = 5) and normal hepatic tissues (n = 5), which were immunohistochemically assessed for AhR expression. Significantly stronger AhR staining was observed for hepatocellular carcinoma tissues than for cancer adjacent normal hepatic tissues (P = 0.003) and normal hepatic tissues (P = 0.004). In addition, AhR expression was associated with T stage (P = 0.03). The results from this study suggest that an increase in AhR expression is associated with hepatocellular carcinoma progression and may have a potential role in the treatment of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23547017     DOI: 10.1007/s10735-013-9495-6

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  46 in total

1.  Expression of the aryl hydrocarbon receptor is not required for the proliferation, migration, invasion, or estrogen-dependent tumorigenesis of MCF-7 breast cancer cells.

Authors:  Barbara C Spink; James A Bennett; Nicole Lostritto; Jacquelyn R Cole; David C Spink
Journal:  Mol Carcinog       Date:  2012-03-02       Impact factor: 4.784

Review 2.  Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

Authors:  George V Papatheodoridis; Pietro Lampertico; Spilios Manolakopoulos; Anna Lok
Journal:  J Hepatol       Date:  2010-04-27       Impact factor: 25.083

3.  The effect of aryl hydrocarbon receptor ligands on the expression of polymerase (DNA directed) kappa (Polκ), polymerase RNA II (DNA directed) polypeptide A (PolR2a), CYP1B1 and CYP1A1 genes in rat liver.

Authors:  Damian Brauze; Agnieszka Anna Rawłuszko
Journal:  Environ Toxicol Pharmacol       Date:  2012-09-16       Impact factor: 4.860

Review 4.  Cytokines as molecular targets for aryl hydrocarbon receptor ligands: implications for toxicity and xenobiotic detoxification.

Authors:  Olivier Fardel
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-12-12       Impact factor: 4.481

5.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.

Authors:  Christiane A Opitz; Ulrike M Litzenburger; Felix Sahm; Martina Ott; Isabel Tritschler; Saskia Trump; Theresa Schumacher; Leonie Jestaedt; Dieter Schrenk; Michael Weller; Manfred Jugold; Gilles J Guillemin; Christine L Miller; Christian Lutz; Bernhard Radlwimmer; Irina Lehmann; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

6.  Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.

Authors:  Shelli M Morris; Ji Yeon Baek; Amanda Koszarek; Samornmas Kanngurn; Sue E Knoblaugh; William M Grady
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

7.  Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands.

Authors:  Kaname Kawajiri; Yasuhito Kobayashi; Fumiaki Ohtake; Togo Ikuta; Yoshibumi Matsushima; Junsei Mimura; Sven Pettersson; Richard S Pollenz; Toshiyuki Sakaki; Takatsugu Hirokawa; Tetsu Akiyama; Masafumi Kurosumi; Lorenz Poellinger; Shigeaki Kato; Yoshiaki Fujii-Kuriyama
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

Review 8.  Ligand binding and activation of the Ah receptor.

Authors:  Michael S Denison; Alessandro Pandini; Scott R Nagy; Enoch P Baldwin; Laura Bonati
Journal:  Chem Biol Interact       Date:  2002-09-20       Impact factor: 5.192

9.  Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target.

Authors:  Jang-Ming Su; Pinpin Lin; Chien-Kai Wang; Han Chang
Journal:  Anticancer Res       Date:  2009-02       Impact factor: 2.480

10.  High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer.

Authors:  Runqiu Jiang; Yongxiang Xia; Jun Li; Lei Deng; Liang Zhao; Jian Shi; Xuehao Wang; Beicheng Sun
Journal:  Int J Cancer       Date:  2010-03-01       Impact factor: 7.396

View more
  19 in total

1.  The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2.

Authors:  Xiaoqin Lan; Fang Xiao; Qiang Ding; Jiqiao Liu; Jingmei Liu; Junhua Li; Jiong Zhang; De-An Tian
Journal:  J Mol Histol       Date:  2014-08-24       Impact factor: 2.611

Review 2.  Aryl hydrocarbon receptor ligands in cancer: friend and foe.

Authors:  Iain A Murray; Andrew D Patterson; Gary H Perdew
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

3.  The RNA-binding protein Sam68 regulates tumor cell viability and hepatic carcinogenesis by inhibiting the transcriptional activity of FOXOs.

Authors:  Tingting Zhang; Chunhua Wan; Weidong Shi; Jian Xu; Hui Fan; Shusen Zhang; Zhipeng Lin; Runzhou Ni; Xiubing Zhang
Journal:  J Mol Histol       Date:  2015-10-05       Impact factor: 2.611

4.  Cell expression patterns of CD147 in N-diethylnitrosamine/phenobarbital-induced mouse hepatocellular carcinoma.

Authors:  Meng Lu; Jiao Wu; Feng He; Xi-Long Wang; Can Li; Zhi-Nan Chen; Huijie Bian
Journal:  J Mol Histol       Date:  2014-12-02       Impact factor: 2.611

5.  Upregulated expression of ubiquitin-conjugating enzyme E2Q1 (UBE2Q1) is associated with enhanced cell proliferation and poor prognosis in human hapatocellular carcinoma.

Authors:  Renan Chang; Lixian Wei; Yuhua Lu; Xiaopeng Cui; Cuihua Lu; Luoliang Liu; Dawei Jiang; YiCheng Xiong; Gang Wang; Chunhua Wan; Haixin Qian
Journal:  J Mol Histol       Date:  2014-10-14       Impact factor: 2.611

6.  Decreased expression of SERPINB1 correlates with tumor invasion and poor prognosis in hepatocellular carcinoma.

Authors:  Xiaopeng Cui; Yanhua Liu; Chunhua Wan; Cuihua Lu; Jing Cai; Song He; Tingting Ni; Junya Zhu; Lixian Wei; Yixin Zhang; Haixin Qian
Journal:  J Mol Histol       Date:  2013-10-09       Impact factor: 2.611

7.  The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables.

Authors:  Gulay Turan; Ceyda Sancakli Usta; Akin Usta; Mehmet Kanter; Lema Tavli; Meric Karacan; Cetin Celik; Metin Eser
Journal:  J Mol Histol       Date:  2014-08-09       Impact factor: 2.611

Review 8.  Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.

Authors:  Lukas Kraehenbuehl; Chien-Huan Weng; Shabnam Eghbali; Jedd D Wolchok; Taha Merghoub
Journal:  Nat Rev Clin Oncol       Date:  2021-09-27       Impact factor: 66.675

Review 9.  The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Brian J North; Kaixiong Tao; Pengbo Zhou; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-12-30       Impact factor: 10.680

10.  A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.

Authors:  Zhuomao Mo; Pan Li; Zhirui Cao; Shijun Zhang
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.